Skip to main content
  • Main menu
  • Home
  • About us
    • About IOF
    • The Board
    • The Executive Committee
    • Regional Representation
    • The Committees
    • The Staff
    • Annual Report
    • Contact us
    • Logo & Brand Guidelines
    • IOF position on conflict zone-collaborations
  • What we do
    • Science & Research
      • Latest News
      • Capture the Fracture®
      • IOF Academy
      • Latest Projects
      • Working Groups
      • Journals
      • Awards
      • WHO ESCEO Agreement
    • Policy & Advocacy
      • Latest News
      • World Osteoporosis Day
      • IOF Global Patient Charter
      • Improve your knowledge
      • IOF Compendium of Osteoporosis
      • WHO ESCEO Agreement
    • Meetings & Events
    • Education
  • Educational hub
  • Thematic menu
  • Patients
    • Patients Homepage
    • IOF Osteoporosis Risk Check
    • About Osteoporosis
    • Prevention
    • Diagnosis
    • Treatment
    • Patient resources
    • Bone Healthy Recipes
    • Facts & Statistics
    • World Osteoporosis Day
    • Patient Stories
    • Find your National Society
    • IOF Global Patient Charter
    • Subscribe to our Newsletter
  • Health Professionals
    • Health Professionals Homepage
    • Latest News
    • Osteoporosis
      • About Osteoporosis
      • Prevention
      • Diagnosis
      • Treatment
    • Fragility Fractures
      • About
      • Epidemiology
      • Vertebral Fractures
      • Treatment & Surgery
      • Models of Care
      • Falls Prevention
    • Facts & Statistics
    • Capture the Fracture®
    • Fundamentals of Osteoporosis Course
    • Meetings & Events
    • CSA Working Groups
    • Articles & Position Papers
    • Educational Materials
    • Research Tools
    • Patient Resources
    • Journals
    • Skeletal Rare Disorders
    • Osteoporosis and Covid-19
  • Policy Makers
    • Policy Makers Homepage
    • Burden of Osteoporosis
    • Facts & Statistics
    • Fracture Liaison Services (FLS)
    • IOF Global Patient Charter
    • Policy Reports & Audits
    • IOF Alliances
    • World Osteoporosis Day
    • Patient Stories
  • Our Network
    • Our Network Homepage
    • The Committees
    • Fracture Liaison Services (FLS)
    • Latest News
    • IOF Alliances
    • Corporate Partners
    • Subscribe to our Newsletter
    • IOF Universities Network
  • IOF Platforms
  • Capture the Fracture®
  • World Osteoporosis Day
  • Fundamentals of Osteoporosis Course
  • Latin America
  • IOF Academy
  • Build Better Bones
IOF International Osteoporosis Foundation
  1. Home
  2. What we do
  3. Science and research
  4. Latest projects - HipGen
Join us !

Social menu

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • YouTube
Donate
Share
  1. Home
  2. What we do
  3. Science and research
  4. Latest projects - HipGen

Latest Projects

Hipgen Project

 
Hipgen
HIPGEN is a multicenter phase III trial which aims to bring the first regenerative therapy for improving recovery following a surgically treated injury to market approval. The new innovative therapy proposed (which is in advanced clinical development stage) is called allogenic placental cell therapy with PLX-PAD cells for the enhanced recovery following hip fracture surgery.
 

The HIPGEN project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779293.

IOF is a member of the HIPGEN alliance, a network of 10 partners from eight countries, primarily with expertise in the fields of cell therapy development and clinical research in the field of orthopaedics. The International Osteoporosis Foundation’s role in the consortium is to fill the communication gap between science and patients. 

For complete information about the project visit the HipGen website the list of partners, visit the website.

View a report on the final meeting of September 12/13, 2022 in Brussels 

View the video of the Public Session on September 13, 2022

HIPGEN Objectives:
Hip fractures are a major public health concern, with high direct and indirect costs due to the resulting immobility after fracture and surgery, and a mortality comparing to cancer with up to 30% during the first year. At present, there is no therapy available to address the problem of impaired regeneration and mobility and the consequences, including high mortality, after hip fracture surgery.

HIPGEN will work to:
Confirm safety and efficacy of PLX-PAD cell therapy in patients undergoing arthroplasty for hip fracture by means of a randomized, double-blind, multicentre, placebo-controlled, phase III study.
Challenge and widen the immunomodulatory mode of action (MoA), seen in a recent phase I/IIa trial, in a larger group of patients with diverse background in adaptive immunity (“immune aging”) and correlate the efficacy of the treatment to patients´ immune experience using a well standardised immune monitoring approach.

  • Evaluate the degree of immune-mediated mechanisms exerted by the standardized PLX-PAD product in muscle regeneration.
  • Define by in vitro and ex vivo MoA studies the PLX-PAD immune-mediated consequences on muscle tissue structure and function through a reshaped pro-regenerative environment
  • Create a strategic engagement of the patients and family as early adopters to the cell product and foster patient and family centered care
  • Achieve a role model for combating major trauma/surgery-related challenged immune balance in elderly patients with poor clinical outcome, like after any major surgery in elderly patients

The successful completion of the phase III study would enable market entry in the hip fracture indication.

9, rue Juste-Olivier
CH-1260 Nyon - Switzerland
+41 22 994 0100
info@osteoporosis.foundation
Follow us
  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • YouTube
© 2025 International Osteoporosis Foundation
Cookie Policy - Privacy policy